Fungal infections in children with haematologic malignancies and stem cell transplant recipients
- PMID: 32159231
- PMCID: PMC7231650
- DOI: 10.1111/bjh.16452
Fungal infections in children with haematologic malignancies and stem cell transplant recipients
Abstract
Children with haematologic malignancies and haematopoietic stem cell transplant recipients are at high risk for invasive fungal diseases (IFD). There has been an increased number of at-risk children over the past two decades due to improvements in cancer therapies resulting in improved survival of children with high-risk and refractory malignancies. The predominant organisms that cause IFD include Candida spp., Aspergillus spp. and the Mucorales molds. Clinical presentations of IFD vary based on host immune status and the causative organism. Though serum biomarkers such as the galactomannan assay and beta-D-glucan assay have been validated in adults, there are limited data regarding their diagnostic value in children. Thus, the gold standard for IFD diagnosis remains tissue biopsy with histopathological and microbiological evaluation. Treatment of IFD is multimodal and involves antifungal drugs, correction of immune dysfunction and surgical resection when feasible. Paediatric practice regarding IFD is largely extrapolated from data generated in adult patients; in this review, we evaluate both primary paediatric studies and guidelines intended for adult patients that are applied to paediatric patients. There remain significant knowledge gaps with respect to the prevention, diagnosis and treatment of IFD in immunocompromised children, and further research is needed to help guide management decisions.
Keywords: antifungal prophylaxis; hematologic malignancies; immunocompromised; invasive fungal disease; pediatric.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.
Figures
References
-
- Afzal S, Ethier MC, Dupuis LL, Tang L, Punnett AS, Richardson SE, Allen U, Abla O & Sung L (2009) Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J, 28, 1064–1068. - PubMed
-
- Arendrup MC, Cuenca-Estrella M, Lass-Florl C & Hope WW (2013) Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat, 16, 81–95. - PubMed
-
- Azik FM, Tezer H, Ozkaya-Parlakay A, Aksu T, Bayram C, Fettah A, Tavil B & Tunc B (2015) Secondary antifungal prophylaxis in pediatric hematopoietic stem cell transplants. J Pediatr Hematol Oncol, 37, e19–22. - PubMed
-
- Barg AA, Malkiel S, Bartuv M, Greenberg G, Toren A & Keller N (2018) Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer, 65, e27281. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
